• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Medical Device
  • First Hong Kong Medical Device Approved for Clinical Use in the Greater Bay Area

First Hong Kong Medical Device Approved for Clinical Use in the Greater Bay Area

Friday, 23 April 2021 / Published in Medical Device, News, NMPA Registration in China

First Hong Kong Medical Device Approved for Clinical Use in the Greater Bay Area

On April 19, the Guangdong MPA (Medical Products Administration) announced the first approved drug product and medical device arriving at the University of Hong Kong – Shenzhen Hospital (HKU-SZH). The drug is an Anti-D (Rho) immunoglobulin injection product and the medical device is a magnetically controlled growing titanium rod. Both products have already been delivered to the HKU-SZH on April 16 for clinical use.

This is a major breakthrough since the Greater Bay Area initiative (currently known as the 港澳药械通 policy in Chinese) was announced by the Chinese and Hong Kong governments to permit the use of Hong Kong-registered drugs and medical devices in designated Hong Kong-owned healthcare institutions in the Greater Bay Area – without prior NMPA registration.

In addition, 54 imported new drugs and medical devices from Hong Kong were selected by the HKU-SZH (reported by Shenzhen Daily on March 24, 2021), and are currently being reviewed by the Guangdong MPA for approval. According to Dr. Lo Chung-mau, the chief executive of the HKU-SZH, the medical devices cover orthopaedic, cardiovascular and surgical products and are selected based on the following factors:

  • Products urgently needed for clinical use
  • Products cannot be substituted in China
  • Products featuring functionalities better than the currently existing products in China to treat patients

Dr. Lo Chung-mau also indicated that the 54 imported products could be accessible in the HKU-SZH as soon as June 2021.

The details of the 54 products or how they were selected has not yet been revealed but it is an interesting development in the Greater Bay Area regulatory pathway.

Cisema recently held a webinar with where we discussed the Greater Bay Area pathway in more detail. You are invited to watch the recording here.

By Jacky Li. Contact Cisema if you would like to learn more.

Tagged under: Greater Bay Area

What you can read next

China Medical Device Standards
December 2021 Regulatory Roundup for Medical Device Mandatory Standards
Administrative Measure on Cosmetics Registration and Filing
NMPA Publishes 6 Regulatory Drafts Concerning Clinical Trials for Medical Devices and IVDs

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • China medical device sampling inspection results

    China medical device sampling inspection results no.4 of 2022

    China medical device sampling inspection result...
  • NMPA cosmetic sampling inspection

    The NMPA Cosmetic Sampling Inspection measures come into force on March 1, 2023

    NMPA Cosmetic Sampling Inspection Measures come...
  • China cosmetics quality safety responsibilities

    China cosmetics quality and safety responsibilities regulations released

    China cosmetics quality and safety responsibili...
  • China cosmetics efficacy claims FAQ

    China cosmetics efficacy claims FAQ available to answer key questions

    China cosmetics efficacy claims FAQ is availabl...
  • China cosmetics GMP inspections

    China cosmetics GMP inspections points have been finalised

    China cosmetics GMP inspections points and judg...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP
Cookies on Cisema
Learn more about Cisema's Privacy Policy.